WTF Wegovy!!!

10 snips

Dec 23, 2024

Dive into the whirlwind of controversy surrounding Wegovy, the blockbuster weight loss drug. Discover the heated debate over the approval of its 2.4mg dosage after a contentious trial. Explore the scrutiny from government regulators and global scientists questioning the safety of higher dosages. What role do gastric side effects play in this complex narrative? This podcast is a thought-provoking exploration of the motivations and implications behind the drug, perfect for pondering during the festive season!

Ask episode

AI Snips

Chapters

Transcript

Episode notes

ANECDOTE

Two Mountains Analogy

Bernadette Fisher compares climbing Mount Everest to climbing Mount Warning seven times.
She argues that despite covering the same height, the challenges are vastly different.

INSIGHT

Wegovy Dosage Trial

The Wegovy dosage trial used daily injections instead of the weekly dosage.
Fisher questions how this methodology was approved by regulators, comparing it to the difference between climbing Everest and Mount Warning.

INSIGHT

Daily vs. Weekly Dosage

Novo Nordisk's Wegovy dose-finding study used daily, low-dose injections.
This differs from Wegovy's weekly administration and raises concerns about the study's validity.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

So much controversy is packed into this relatively short Investigating Ozempic Podcast.

How did the weekly administered Wegovy (semaglutide) drug get approved for the higher dosage of 2.4mg after doing a controversial dosage trial that conducted testing daily rather than weekly. Why did the Government Regulators approve this dosage after expressing some concerns and why did World Scientists publish questions over using higher dosages of Semaglutide (GLP1's) for weight loss? Is it all to do with Gastric side effects?

So many questions for the Global Blockbuster Drug Wegovy and so much to think about over the Christmas break.

Contact

investigatingozempic@gmail.com

Special Note

In this Podcast I am ONLY looking at the WEIGHT LOSS EFFECT of these GLP1 drugs and am not looking at the Diabetic effects. This podcast should not be construed as giving any type of medical advice. I am not a qualified health care professional.

Legal and Medical Disclaimer:

The Investigating Ozempic podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user’s own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.

Every care has been taken to obtain accurate information including reaching out to Novo Nordisk for comment - which so far has remained unanswered. I encourage Novo Nordisk to contact me and correct any discrepancies that have been made accidentally and in good faith by the author. This podcast contains my personal opinion which is solely my own and not intended to be construed in any other manner.

Copyright

All rights reserved by Bernadette Fisers. Material in the podcast and any content therein is subject to copyright under Australian law and through international treaties, and applicable law in other countries.

Unless otherwise indicated, we (and/or our third-party licensors) own the copyright and other intellectual property rights in the recording, text, graphics, information, designs, data and other content in this document.

LINKS TO DOCUMENTS MENTIONED

Wegovy Dosage Trial

Ozempic Dosage Trial

2019 Review of GLP1 by 20 Scientists

European Medicines Agency Assessment Report of Wegovy

Novo Nordisk Tosemaglutide daily testing trial in Germany

FDA partially redacted notes on Semaglutide